Novavax, Inc. (NVAX)
| Market Cap | 1.29B |
| Revenue (ttm) | 1.12B |
| Net Income (ttm) | 440.30M |
| Shares Out | 162.94M |
| EPS (ttm) | 2.58 |
| PE Ratio | 3.08 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,289,853 |
| Open | 8.08 |
| Previous Close | 8.07 |
| Day's Range | 7.87 - 8.10 |
| 52-Week Range | 5.80 - 11.97 |
| Beta | 2.65 |
| Analysts | Hold |
| Price Target | 11.33 (+43.06%) |
| Earnings Date | May 8, 2026 |
About NVAX
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for NVAX stock is "Hold." The 12-month stock price target is $11.33, which is an increase of 43.06% from the latest price.
News
Novavax Faces Shareholder Revolt As Shah Capital Criticizes Strategy
The investor, which holds roughly 9% of the company, argued that leadership has failed to translate Novavax's vaccine platform into meaningful commercial success.
Shah Capital intends to vote against Novavax's board nominees, executive compensation
Activist investor Shah Capital plans to vote against the re-election of board nominees and the executive compensation package at Novavax's upcoming annual meeting, renewing pressure for changes at t...
Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical Officer Dr. Walker will continue advancing Novavax's R&D efforts with...
Novavax Transcript: Leerink Global Healthcare Conference 2026
The company has pivoted to a partnership-driven model, leveraging its Matrix-M technology to secure major deals with Sanofi and Pfizer, and is advancing a robust R&D pipeline targeting vaccines and immunotherapies. Financial discipline and strong IP position support a path to profitability by 2028.
Novavax Transcript: TD Cowen 46th Annual Health Care Conference
The company has pivoted to a platform and partnership-driven strategy, highlighted by major deals with Sanofi and Pfizer, expansion of its Matrix-M adjuvant platform, and a robust early-stage pipeline. Financially, it targets profitability by 2028, supported by a strong cash runway and cost reductions.
What's Going On With Novavax Stock On Friday?
Novavax Inc. (NASDAQ: NVAX) shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 finan...
Novavax to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that it will participate in the following upcoming investor conferences: TD Cowen 46 th Annual Health Car...
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb
Novavax Inc. (NASDAQ: NVAX) shares are up on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.
Novavax Earnings Call Transcript: Q4 2025
Revenue grew 65% year-over-year to $1.1B in 2025, driven by partnerships and cost reductions. Cash runway extends into 2028, with 2026 revenue guidance of $230–$270M and further expense cuts planned. Matrix-M technology and new deals with Pfizer and Sanofi underpin future growth.
Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals
Novavax raised its adjusted revenue forecast for 2026 on Thursday, as it expects milestone payments from vaccine supply and licensing deals to offset pressure from sagging demand.
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmace...
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 ...
Novavax Announces Entering into a License Agreement with Pfizer
Non-exclusive license allows for development by Pfizer to utilize Matrix-M ® for up to two disease areas with its products Provides Novavax with an upfront payment of $30 million with the potential fo...
Novavax enters license agreement with Pfizer for vaccine development
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for infectious diseases.
Novavax Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company has transformed from a single-asset focus to a diversified platform strategy, achieving major cost reductions and expanding partnerships with leading pharma companies. Key catalysts for 2026 include Sanofi’s full U.S. launch, new partnership opportunities, and advancing early-stage pipeline assets.
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md., Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the 44th Annual J.P.
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Memo also reportedly mentions vaccines for flu and pneumonia.
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals
The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.
Novavax Transcript: Jefferies London Healthcare Conference 2025
A strategic shift is underway, focusing on partnerships, notably with Sanofi, to commercialize vaccines and leverage the Matrix-M adjuvant platform. The pipeline targets high unmet needs in infectious disease and oncology, with AI-driven innovation and multiple pharma collaborations.
Shah Capital pushes for Novavax sale, warns of proxy fight
Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no progress is ...
Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md. , Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference: Jefferies London Healthcare Confe...
Novavax Earnings Call Transcript: Q3 2025
Q3 2025 saw continued transformation with a shift to a partnership and R&D-driven model, highlighted by expanded Sanofi collaboration, cost reductions, and a diversified pipeline. Revenue was $70M, with a net loss of $202M, and 2025 guidance was raised. Non-GAAP profitability is now targeted for 2028.
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Total revenue of $70 million in the third quarter of 2025 Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date including $50 million earned on mar...
Novavax raises annual revenue forecast on strength of vaccine deals
Novavax raised its annual revenue forecast for the third time this year on Thursday, banking on milestone payments from vaccine supply and licensing deals such as with Japan's Takeda Pharmaceuticals.